Share price · MRK
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MRK's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 5 Oct 2026-3.3%
Nothing announced by MRK that day or the session before.
- 25 Aug 2026+3.8%
Nothing announced by MRK that day or the session before.
- 19 Aug 2026+12.6%
- Day beforePliant Therapeutics, Inc.: Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid TumorsPLRX +1.7%
- 1 Jul 2026-2.4%
Nothing announced by MRK that day or the session before.
- 15 Jun 2026-3.5%
Nothing announced by MRK that day or the session before.
- 22 May 2026+5.6%
- Day beforeBioInvent International AB: BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA® (pembrolizumab) in Advanced Ovarian Cancer at ASCOBINV -0.7%
- 1 May 2026+2.7%
- 21 Apr 2026-3.9%
- 3 Feb 2026+2.2%
- 8 Jan 2026+2.2%
Nothing announced by MRK that day or the session before.
Share of unusual movement by asset
For each asset, the share of MRK's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(54 total)
| Target & Modality | |||
|---|---|---|---|
Belzutifan(Welireg) | Approved | HIF-2alphaSmall molecule | Renal Cell Carcinoma |
Clesrovimab(Enflonsia) | Approved | RSV F proteinMonoclonal antibody | Respiratory Syncytial Virus Infection |
Doravirine(Pifeltro) | Approved | HIV reverse transcriptaseSmall molecule | HIV |
| Approved | HIV reverse transcriptase · HIV-1 Reverse TranscriptaseSmall molecule | HIV | |
ensifentrine(Ohtuvayre) | Approved | PDE3/PDE4Small molecule | Chronic Obstructive Pulmonary Disease |
Ertugliflozin(Steglatro) | Approved | SGLT2Small molecule | Type 2 Diabetes |
| Approved | Type I interferon receptorBiologic (subtype unspecified) | Chronic Hepatitis BFollicular LymphomaMelanoma | |
mometasone furoate/formoterol fumarate(Dulera / Zenhale) | Approved | Glucocorticoid receptor; Beta-2 adrenergic receptorSmall molecule | Asthma |
| Approved | PARPSmall molecule | Breast CancerMetastatic Castration-Resistant Prostate CancerOvarian CancerPancreatic CancerProstate Cancer HR+/HER2- Metastatic Breast Cancer | |
| Approved | PD-1Monoclonal antibody | Non-Small Cell Lung CancerBreast CancerOvarian CancerCervical CancerHepatocellular CarcinomaColorectal CancerMerkel Cell CarcinomaBiliary Tract CancerNon-Hodgkin LymphomaGastric CancerHead and Neck Squamous Cell CarcinomaSolid TumorsBladder / Urothelial CancerRenal Cell CarcinomaMelanomaEndometrial CancerEsophageal Cancer HR+/HER2- Metastatic Breast Cancer, Large B-Cell Lymphoma, Urothelial Carcinoma, Metastatic Colorectal Cancer, Esophageal Squamous Cell Carcinoma, Non-Muscle Invasive Bladder Cancer | |
Pembrolizumab berahyaluronidase alfa(Keytruda Qlex) | Approved | PD-1Monoclonal antibody | Non-Small Cell Lung CancerCervical CancerColorectal CancerBladder CancerGastric CancerSolid TumorsBreast CancerRenal Cell CarcinomaMelanoma |
Raltegravir(Isentress) | Approved | HIV integraseSmall molecule | HIV |
Riociguat(Adempas) | Approved | Soluble guanylate cyclaseSmall molecule | Pulmonary Arterial Hypertension |
Sitagliptin(Januvia) | Approved | DPP-4Small molecule | Type 2 Diabetes |
Sotatercept(Winrevair) | Approved | Activin receptor type IIA (ActRIIA)Protein / enzyme therapeutic | Heart FailurePulmonary Arterial Hypertension |
Upcoming events
(189 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (5)
November 2026 (1)
What to watch
December 2026 (4)
2027 (54)
January 2027 (2)
February 2027 (4)
What to watch
What to watch
What to watch
What to watch
March 2027 (3)
April 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
May 2027 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
June 2027 (3)
July 2027 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
August 2027 (3)
September 2027 (4)
What to watch
What to watch
What to watch
What to watch
October 2027 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
November 2027 (3)
2028 (40)
January 2028 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
February 2028 (4)
What to watch
What to watch
What to watch
What to watch
March 2028 (2)
What to watch
What to watch
April 2028 (1)
What to watch
May 2028 (2)
What to watch
What to watch
June 2028 (4)
July 2028 (3)
August 2028 (2)
September 2028 (4)
October 2028 (2)
November 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
2029 (37)
January 2029 (3)
What to watch
What to watch
What to watch
February 2029 (3)
March 2029 (4)
What to watch
What to watch
What to watch
What to watch
April 2029 (5)
May 2029 (3)
What to watch
What to watch
What to watch
June 2029 (1)
What to watch
July 2029 (5)
What to watch
What to watch
What to watch
What to watch
August 2029 (2)
September 2029 (1)
What to watch
October 2029 (3)
What to watch
What to watch
What to watch
November 2029 (2)
December 2029 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
2030 (7)
January 2030 (1)
What to watch
May 2030 (1)
What to watch
June 2030 (1)
What to watch
November 2030 (2)
What to watch
What to watch
2031 (13)
January 2031 (2)
What to watch
What to watch
July 2031 (1)
What to watch
August 2031 (2)
September 2031 (3)
What to watch
What to watch
October 2031 (3)
November 2031 (1)
What to watch
2032 (18)
January 2032 (1)
What to watch
February 2032 (3)
What to watch
What to watch
What to watch
March 2032 (4)
What to watch
What to watch
What to watch
What to watch
April 2032 (1)
What to watch
May 2032 (1)
What to watch
June 2032 (3)
What to watch
What to watch
What to watch
August 2032 (1)
What to watch
September 2032 (1)
What to watch
November 2032 (2)
What to watch
What to watch
December 2032 (1)
What to watch
2033 (5)
February 2033 (1)
What to watch
March 2033 (1)
What to watch
May 2033 (1)
What to watch
July 2033 (1)
What to watch
December 2033 (1)
What to watch
2034 (5)
January 2034 (1)
What to watch
February 2034 (1)
What to watch
April 2034 (1)
What to watch
August 2034 (1)
What to watch
December 2034 (1)
What to watch
2035 (1)
August 2035 (1)
What to watch
2037 (2)
2039 (1)
October 2039 (1)
What to watch
2043 (1)
August 2043 (1)
What to watch
Regulatory and conference events
(27)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
The 12 most recent of 27 past events are shown.
Financial reports
Quarterly & interim (18)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $18.1B | $4.5B | $9.7B+ $100M short-term inv. | —$6.6B operating cash flow | report ↗ |
View 17 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $16.6B | $9.7B | $6.9B+ $292M short-term inv. | $1.3B$5.4B operating cash flow | report ↗ |
| 2026-Q1 | $16.3B | $12.6B | $5.4B+ $375M short-term inv. | $4.2B$3.9B operating cash flow | report ↗ |
| 2025-Q4 | $16.4B | $3.9B | $14.6B | — | report ↗ |
| 2025-Q3 | $17.3B | $4.2B | $18.2B+ $45M short-term inv. | —$7.8B operating cash flow | report ↗ |
| 2025-Q2 | $15.8B | $4.0B | $8.6B+ $615M short-term inv. | —$3.3B operating cash flow | report ↗ |
| 2025-Q1 | $15.5B | $3.6B | $9.2B+ $599M short-term inv. | —$2.5B operating cash flow | report ↗ |
| 2024-Q4 | $15.6B | $4.6B | $13.7B | — | report ↗ |
| 2024-Q3 | $16.7B | $5.9B | $14.6B+ $0 short-term inv. | —$9.3B operating cash flow | report ↗ |
| 2024-Q2 | $16.1B | $3.5B | $11.4B+ $50M short-term inv. | —$5.6B operating cash flow | report ↗ |
| 2024-Q1 | $15.8B | $4.0B | $5.7B+ $40M short-term inv. | —$3.1B operating cash flow | report ↗ |
| 2023-Q3 | $16.0B | $3.3B | $8.7B+ $168M short-term inv. | —$7.7B operating cash flow | report ↗ |
| 2023-Q2 | $15.0B | $13.3B | $5.7B+ $718M short-term inv. | $6.0B$3.7B operating cash flow | report ↗ |
| 2023-Q1 | $14.5B | $4.3B | $9.8B+ $680M short-term inv. | —$1.3B operating cash flow | report ↗ |
| 2022-Q3 | $15.0B | $4.4B | $11.3B+ $103M short-term inv. | —$5.6B operating cash flow | report ↗ |
| 2022-Q2 | $14.6B | $2.8B | $9.8B+ $453M short-term inv. | —$4.3B operating cash flow | report ↗ |
| 2022-Q1 | $15.9B | $2.6B | $8.6B+ $372M short-term inv. | —$4.8B operating cash flow | report ↗ |
| 2021-Q3 | $13.2B | $2.4B | $10.0B | — | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $65.0B | $15.8B | $14.6B+ $0 short-term inv. | —$16.5B operating cash flow | report ↗ |
Merck reported full-year 2025 revenue of $65,011M, up 1% YoY, with R&D spend of $15,789M, down 12% YoY, and cash and equivalents of $14,565M. GAAP net income was $18,254M, with GAAP EPS of $7.28 and non-GAAP EPS of $8.98.
The company guided full-year 2026 sales to $65.5B–$67.0B and non-GAAP EPS to $5.00–$5.15, including a one-time charge of approximately $3.65 per share related to the Cidara acquisition. It highlighted positive results from 18 Phase 3 trials in 2025, including enlicitide, doravirine/islatravir, and KEYTRUDA-based regimens; advanced WINREVAIR and sac-TMT regulatory milestones; and expanded its pipeline through acquisitions of Verona Pharma and Cidara Therapeutics, a license agreement with Hengrui Pharma, and a U.S. government agreement to broaden medicine access and lower costs.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $64.2B | $17.9B | $13.7B+ $447M short-term inv. | —$21.5B operating cash flow | report ↗ |
| 2023-FY | $60.1B | $30.5B | $7.1B+ $252M short-term inv. | —$13.0B operating cash flow | report ↗ |
| 2022-FY | $59.3B | $13.5B | $12.8B+ $498M short-term inv. | —$19.1B operating cash flow | report ↗ |
| 2021-FY | $48.7B | $12.2B | $8.2B+ $0 short-term inv. | — | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 34 sales ($79.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-12 | DeLuca Richard R. · EVP&Pres, Merck Animal Heallth | Option exercise | 58,185 | $77.62 | $4.5M | Form 4 |
| 2026-11-12 | DeLuca Richard R. · EVP&Pres, Merck Animal Heallth | Open-market sale | 58,185 | $148.01 | $8.6M | Form 4 |
| 2026-11-12 | DeLuca Richard R. · EVP&Pres, Merck Animal Heallth | Option exercise (derivative) | 58,185 | — | — | Form 4 |
| 2026-11-01 | DIAZ PAUL J · director | Award / grant (derivative) | 613.073 | $149.52 | $92K | Form 4 |
| 2026-09-30 | Coe Mary Ellen · director | Award / grant (derivative) | 206.455 | $145.31 | $30K | Form 4 |
| 2026-09-30 | Karsanbhai Surendralal Lanca · director | Award / grant (derivative) | 111.83 | $145.31 | $16K | Form 4 |
| 2026-09-30 | Seidman Christine E · director | Award / grant (derivative) | 55.915 | $145.31 | $8K | Form 4 |
| 2026-08-13 | Guindo Chirfi · EVP, Access, Policy & Comms | Open-market sale | 10,000 | $135.00 | $1.4M | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 3,694 reporting institutions held 1924.2M shares ($221.8B, 78.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 225,830,330 | $27.2B |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 160,987,624 | $19.4B |
| 3 | STATE STREET CORP | 119,325,673 | $14.5B |
| 4 | WELLINGTON MANAGEMENT GROUP LLP | 84,314,971 | $10.1B |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 67,304,305 | $8.1B |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 59,558,154 | $7.1B |
| 7 | JPMORGAN CHASE & CO | 52,972,983 | $6.3B |
| 8 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 49,765,225 | $6.0B |
| 9 | MORGAN STANLEY | 47,632,487 | $5.7B |
| 10 | FMR LLC | 44,516,010 | $5.4B |
| 11 | BANK OF AMERICA CORP /DE/ | 30,774,221 | $3.7B |
| 12 | NORTHERN TRUST CORP | 27,090,023 | $3.3B |
| 13 | Fisher Asset Management, LLC | 26,436,284 | $3.2B |
| 14 | Invesco Ltd. | 21,855,101 | $2.6B |
| 15 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 20,414,819 | $2.5B |